Pacs Group Inc (PACS) valuation
Pacs Group P/E ratio history
Pacs Group trades at 28.0 times its earnings over the last twelve months and 18.2 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $38.39 | $1.22 | 31.5 | 18.2 |
| Dec 31, 2024 | $13.11 | $0.38 | 34.5 | 7.7 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Pacs Group valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Pacs GroupPACS | $7.57B | 28.0 | 18.2 | 1.4 |
| AlkermesALKS | $7.56B | 119.3 | 29.4 | 4.5 |
| Axsome TherapeuticsAXSM | $7.43B | — | — | 9.6 |
| CytokineticsCYTK | $7.84B | — | — | 115.8 |
| Praxis Precision MedicinesPRAX | $7.97B | — | — | — |
| Amneal PharmaceuticalsAMRX | $6.86B | 44.8 | 19.2 | 2.2 |
| Spyre TherapeuticsSYRE | $8.38B | — | — | — |
| Arrowhead PharmaceuticalsARWR | $8.44B | — | — | 12.6 |
| HealthequityHQY | $8.57B | 37.0 | 20.0 | 6.3 |
| Peer median | 44.8 | 20.0 | 7.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PACS financials · PACS returns
No forecast, no recommendation. This page describes Pacs Group Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.